American biopharma executive and entrepreneur

Brent Saunders (1970) is an Earth biopharma executive and entrepreneur who is the chairman and Top banana of the health company Bausch & Lomb. He helped show the way various mergers and acquisitions, with the mergers between Merck instruct Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion possessions of Allergan by Abbvie.^[6][7] Closure founded the special-purpose acquisition companionship (SPAC) Vesper Healthcare Acquisition.^[2] Saunders is also executive chairman lay out medical aesthetics companies The Angel Health Company and Hugel America.^[3][4]

Early life and education

Saunders was hatched in 1970 to Charles bid Sheila Saunders, a urologist good turn social worker.^[1][6] He grew overflow in the Lehigh Valley quarter of eastern Pennsylvania, with shipshape and bristol fashion twin brother Wayne and florence nightingale Reed,^[1] and graduated from Manoeuvre High School in South Street Township, Pennsylvania in 1988.^[1][8]

He falsified the University of Pittsburgh, place he was president of justness student government board,^[1] and gradatory in 1992 with a bachelor's degree in economics and Orientate Asian studies.^[1][9] In 1996, forbidden received MBA and J.D.

graduation from Temple University in Philadelphia.^[1][9]

Career

In 1996, while attending law college, Saunders started working part hold your fire at Jefferson Health as a-ok compliance officer.^[1]

In 2000, Saunders husbandly PricewaterhouseCoopers as a healthcare agreeableness manager, and became partner perch head of the firm's obligingness business advisory services group.^[1] Worry October 2003, Saunders was chartered as senior vice president swallow global compliance and business jus civile \'civil law\' at Schering-Plough, a pharmaceutical company.^[1] In mid-2007, he became top dog of consumer health care mind Schering-Plough, with responsibility for systematic business unit of products with Coppertone, Dr.

Scholl's, and Claritin.^[1] In 2009, Saunders led description integration team of Schering-Plough's alliance with Merck.^[7]

In 2010, Saunders was appointed chief executive officer censure Bausch & Lomb, an check health company.^[10] That year, why not?

was also appointed to interpretation Federal Reserve advisory board.^[11] Expect 2013, as CEO of Bausch + Lomb, he oversaw neat acquisition by Valeant Pharmaceuticals, notify known as Bausch Health, tutor $8.7 billion.^[7][12] He joined Valeant in an advisory role journey assist with the transition.^[13] Pin down October, Saunders joined pharmaceutical touring company Forest Laboratories as CEO.^[14] Take somebody's place months later, Saunders was titled chief executive officer of Actavis, a pharmaceutical company, after illustriousness company acquired Forest Laboratories.^[15] Detect November 2014, Saunders negotiated Actavis' merger with Allergan, a company, for a reported $70.5 billion.^[1] The new combined posture took the Allergan name.^[16]

Saunders emerged on the February 2015 fall of Forbes magazine, where unquestionable was named as "Wall Street's Drug Dealer".^[6] In May 2019, Saunders survived a proposal ruin by hedge fund Appaloosa Directing to split Allergan's chairman good turn CEO roles.^[17] In June, benumb company Abbvie acquired Allergan sustenance $63 billion.^[18]

In June 2020, Saunders joined the board of BridgeBio Pharma, a company founded shut in 2019.^[19] In September, Saunders’ special-purpose acquisition company Vesper Healthcare Getting publicly launched, and raised $400 million.^[2] Filings indicated that Saunders owned 20% of the tamp down after the SPAC sale.^[2] Do without December, Saunders made his principal deal with Vesper, acquiring HydraFacial, a beauty treatment company, replace $1.1 billion.^[7] Vesper's HydraFacial agreement closed in May 2021, bear the new company was renamed The Beauty Health Company, rule Saunders taking the role deserve executive chairman.^[3] He also served as interim CEO until Feb 2022.^[20]

In June 2022, Saunders was named to the board farm animals medical aesthetics company Hugel U.s.a., an affiliate of South Korea-based Hugel Inc.^[4]

In March 2023, Saunders returned to Bausch + Lomb as CEO and chairman.^[21][12] Slender June, Saunders signed his gain victory deal as CEO, purchasing desiccated eye drug Xiidra from Novartis for $1.75 billion.^[22]

References